期刊文献+

偶联西妥昔单抗的金纳米颗粒治疗非小细胞肺癌 被引量:3

Cetuximab-conjuated gold nanoparticles for the therapy of non-small cell lung cancer
原文传递
导出
摘要 目的 观察偶联西妥昔单抗(C225)的金纳米颗粒(AuNPs)对肺腺癌A549细胞株的作用,研究其对细胞功能以及相关蛋白的影响并探讨其分子机制.方法 应用浓度分别为1、10、100、500 mg/L的C225、偶联IgG的金纳米颗粒(IgG-AuNPs)、偶联C225的金纳米颗粒(C225-AuNPs)处理A549细胞,药物作用24、48 h后通过细胞计数试剂盒(CCK-8)检测细胞抑制率;通过流式细胞仪检测细胞凋亡和周期变化,通过Transwell小室法检测细胞迁移,Western blot检测表皮生长因子受体(EGFR)、蛋白激酶B(Akt)、磷酸化Akt (p-Akt)、细胞外信号调节激酶(ERK)、磷酸化ERK(p-ERK)以及B细胞淋巴瘤/白血病-2(bcl-2)蛋白的表达变化.结果 C225-AuNPs对A549细胞株的抑制率呈剂量依赖性,当浓度达到100 mg/L时,最大抑制率为28%,相对单用IgG-AuNPs和C225,C225-AuNPs显著抑制细胞增殖.100 mg/L的C225-AuNPs作用后A549细胞凋亡率为(27.40±3.54)%,明显高于相同浓度C225的(11.80±2.02)%以及IgG-AuNPs的(9.50±2.76)%;但是C225-AuNPs对细胞周期的影响并不明显;C225-AuNPs处理组后穿膜细胞数目为(94±9)个,与C225组[(155±12)个]以及IgG-AuNPs组[(136±15)个]比较明显减少;通过Western blot检测经过C225-AuNPs处理后p-AKt、p-ERK以及bcl-2蛋白的表达量较C225以及IgG-AuNPs组明显下调.结论 C225-AuNPs显著抑制A549细胞增殖、迁移,促进凋亡,增强A549细胞对C225单抗的敏感性. Objective To investigate whether a specific nanoprobe of epidermal growth factor receptor (EGFR) which conjugating cetuximab to gold nanoparticles can affect physiological activities of A549 cells,and the molecular mechanism.Methods A549 cells were treated with different concentrations of cetuximab (C225),IgG-gold nanoparticles (AuNPs) and C225-AuNPs (1,10,100,500 mg/L).Cell survival was detected by cell counting kit-8 (CCK-8) assay.Apoptotic cells were quantitatively examined using FITC Annexin V apoptosis Detection Kit I.Cell cycle was tested by flow cytometry.The invasion ability was measured through the Transwell method.The protein expression of EGFR,protein kinase B (Akt),p-Akt,extracellular signal-regulated kinase (ERK),p-ERK and B lymphocytes/leukemia-2 (bcl-2) was detected by using Western blotting.Results The cytotoxicity of C225-AuNPs on the lung cancer A549 cells was increased in a dose-dependent manner.C225-AuNPs suppressed proliferation significantly.100 mg/L C225-AuNPs,C225 and IgG-AuNPs increased apoptosis rate to (27.40 ± 3.54) %,(11.80 ± 2.02)% and (9.50 ±2.76)%,respectively.A549 cells treated with 100 mg/L C225-AuNPs had fewer cells penetrating through the membrane than the control groups [C225-AuNPs mean:(94 ± 9) vs.C225 group mean:(155 ± 12) vs.IgG-AuNPs group mean:(136 ± 15)].The expression of p-AKt,p-Erk and bcl-2 was reduced significantly through C225-AuNPs treatments.Conclusion C225-AuNPs suppressed proliferation and invasion,accelerated apoptosis of A549 cells,and increased the sensibility to C225.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第3期580-583,共4页 Chinese Journal of Experimental Surgery
基金 卫生部基金资助项目(W6) 江苏省自然科学重点研究专项基金资助项目(BK2011036) 江苏省科技厅临床科技重点专项基金资助项目(BL2012030)
关键词 西妥昔单抗 金纳米 表皮生长因子受体 靶向治疗 非小细胞肺癌 Cetuximab Gold nanoparticles Epidermal growth factor receptor Targeted therapy Non-small cell lung cancer
  • 相关文献

参考文献10

  • 1傅岳武,潘运龙,覃莉,巫青,刘英梅.纳米金联合5-氟尿嘧啶对裸鼠肝癌血管及肿瘤生长的影响[J].中华实验外科杂志,2013,30(2):271-273. 被引量:4
  • 2吴秀英,管洪庚,兰晶.西妥昔单抗对胃癌细胞增殖和凋亡的影响[J].中华实验外科杂志,2012,29(9):1733-1736. 被引量:4
  • 3倪虹,杨茂,刘文欣,郭志.非小细胞肺癌K—ras突变小分子对吉非替尼耐药细胞的作用[J].中华实验外科杂志,2011,28(6):961-963. 被引量:5
  • 4Pan Y, Leifert A, Ruau D, et al. Gold nanoparticles of diameter 1. 4nm trigger necrosis by oxidative stress and mitochondrial damage [ J].Small,2009’5(18) :2067-2076.
  • 5Mukherjee P,Bhattacharya R, Wang P, et al. Antiangiogenic proper-ties of gold nanoparticles [ J] . Clin Cancer Res,2005 ,11 (9): 3530-3534.
  • 6Brown SD,Nativo P,Smith JA, et al. Gold nanoparticles for the im-proved anticancer drug delivery of the active component of oxaliplatin[J]. J Am Chem Soc ,2010,132 (13) :46784684.
  • 7Prabaharan M, Grailer JJ, Pilla S, et al. Gold nanoparticles with amonolayer of doxorubicin-conjugated amphiphilic block copolymer fortumor-targeted drug delivery [ J]. Biomaterials,2009 ,30(30) :6065-6075.
  • 8Huang SM, Bock JM, Harari PM. Epidermal growth factor receptorblockade with C225 modulates proliferation,apoptosis,and radiosensi-tivity in squamous cell carcinomas of the head and neck[ J]. CancerRes,1999,59(8) : 1935-1940.
  • 9Kao HW,Lin YY, Chen CC,et al. Evaluation of EGFR-targeted radio-immuno-gold-nanoparticles as a theranostic agent in a tumor animalmodel [ J]. Bioorg Med Chem Lett,2013 ,23( 11) :3180-3185.
  • 10胡伟,胡祎,周昆,王跃斌,夏宗江.转化生长因子-β通过PI3K/AKT信号通路促进人肺腺癌细胞株A549的增殖作用[J].中华实验外科杂志,2011,28(8):1241-1243. 被引量:7

二级参考文献29

  • 1潘运龙,覃莉.白细胞介素-12抑制裸鼠肝癌Ang-2和血管内皮生长因子表达及其意义[J].中华实验外科杂志,2005,22(4):439-441. 被引量:10
  • 2Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005,2 : 17.
  • 3Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One ,2009,4:4576.
  • 4Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res ,2009,15:3484-3494.
  • 5Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Nail Acad Sci USA ,2009,106 : 19503-19508.
  • 6Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Clin Invest,2009,119:3000-3010.
  • 7Wei XL, Guo W, Wu SH, et al. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem,2009,284 : 16948-16955.
  • 8Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors:an important role for mutations in minor clones. Neoplasia, 2009,11 : 1084-1092.
  • 9Guo W, Wu S, Liu J, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res,2008, 68:7403-7408.
  • 10Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med, 1997,75:587-593.

共引文献15

同被引文献32

  • 1朱砾,杨洋,刘东雷,郭海周,赵松.自噬在贝伐单抗诱导非小细胞肺癌凋亡中的作用[J].中国老年学杂志,2014,34(9):2489-2491. 被引量:3
  • 2张春芳,陈胜喜,郭海周,罗万俊,许廖梅,何争鸣.肺隔离药物灌注治疗肺癌临床研究[J].中华实验外科杂志,2005,22(4):486-487. 被引量:1
  • 3Sheppard MN.Neuroendocrine differentiation in lung tumours[J].Thorax,1991,46 (11):843-850.
  • 4Rea F,Rizzardi G,Zuin A,et al.Outcome and surgical strategy in bronchial carcinoid tumors:single institution experience with 252 patients[J].Eur J Cardiothorac Surg,2007,31 (2):186-191.
  • 5Rossi G,Cavazza A,Marchioni A,et al.Role of chemotherapy and the receptor tyrosine kinases KIT,PDGFR alpha,PDGFR beta,and Met in large cell neuroendocrine carcinoma of the lung[J].J Clin Oncol,2005,23 (34):8774-8785.
  • 6Jemal A, Bray F, Center MM. Global cancer statistics [J]. CACancerJClin,2011,61(2):69-90.
  • 7Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) : an open-label randomised phase III trial [J]. Lancet, 2009, 373 (9674) : 1525-1531.
  • 8Kim ES, Neubauer M, Cohn A. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non- small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial EJ]. Lancet Oncol, 2013, 14 (13) : 1326-1336.
  • 9Gridelli C, Maione P, Ferrara ML, et al. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer[J]. Oncologist, 2009, 14(6): 601-611.
  • 10Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab [J]. Clin Cancer Res, 2007, 13 (Suppl 15) : 4597-4601.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部